CTLA4Ig：架起基础免疫学与临床应用之间的桥梁。

CTLA4Ig: bridging the basic immunology with clinical application.

作者信息

Bluestone Jeffrey A, St Clair E William, Turka Laurence A

机构信息

Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA.

出版信息

Immunity. 2006 Mar;24(3):233-8. doi: 10.1016/j.immuni.2006.03.001.

DOI:10.1016/j.immuni.2006.03.001

PMID:16546089

Abstract

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

摘要

经过漫长而曲折的道路，2005年12月，美国食品药品监督管理局（FDA）批准了CTLA4Ig用于治疗类风湿性关节炎。恩瑞舒（Orencia）是首个CD28共刺激拮抗剂。从这个角度出发，我们将探讨促成CTLA4Ig研发的科学原理以及将该药物从实验室推向临床应用所面临的挑战。